ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center
<i>ESR1</i> mutations are detectable in approximately one-third of ER+/HER2- metastatic patients undergoing liquid biopsy. NGS platforms allow for sensitive and in-depth analysis, highlighting co-mutations of potential clinical and therapeutic relevance.
Authors
- Giulia Calafato (ORCID: https://orcid.org/0000-0003-0177-238X)
- Antonio De Leo (ORCID: https://orcid.org/0000-0002-3761-5135)
- Claudio Zamagni (ORCID: https://orcid.org/0000-0003-0052-2581)
- Roberta Minari (ORCID: https://orcid.org/0000-0002-4808-0308)
- Elisa Gruppioni (ORCID: https://orcid.org/0000-0002-4334-6170)
- Laura Poppi (ORCID: https://orcid.org/0000-0002-7353-8237)
- Alessandra Bernardi (ORCID: https://orcid.org/0000-0002-6948-1274)
- Sara Coluccelli (ORCID: https://orcid.org/0000-0002-1475-4044)
- Dario de Biase (ORCID: https://orcid.org/0000-0002-0609-8817)
- Thais Maloberti (ORCID: https://orcid.org/0000-0002-8306-4653)
- Viviana Sanza
- Annalisa Altimari (ORCID: https://orcid.org/0000-0001-9944-2455)
- S. Quercia
- Giovanni Tallini (ORCID: https://orcid.org/0000-0003-0113-6682)
- Floriana Jessica Di Paola
- Giulia Ciccimara
Institutions
- University of Parma (IT)
- Azienda USL di Bologna (IT)
- University of Bologna (IT)
Publication Details
- Journal
- The Journal of Liquid Biopsy
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1016/j.jlb.2025.100331
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00